Job Trends
BioSpace data show job postings live increased quarter over quarter, while layoffs fell year over year.
Labor Market Reports
BioSpace’s 2026 U.S. Life Sciences Employment Outlook examines the state of the biopharma workforce amid ongoing funding pressure, elevated layoffs and cautious hiring sentiment, while highlighting early signals of stabilization and cautious optimism for the year ahead.
BioSpace’s 2025 Q4 U.S. Life Sciences Job Market update highlights early signs of stabilization in biopharma hiring, with modest gains in job postings, slowing layoffs, and cautiously improving sentiment heading into 2026.
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
Now Hiring
Looking for an IT job? From data engineer to information security, check out the BioSpace list of 10 companies hiring life sciences professionals like you.
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new BioSpace employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.
Career Advice
If workloads aren’t adjusted as needed, the company’s priorities are already compromised. Executive coach Angela Justice explores what happens when goals move forward without removing unnecessary work and what to do about it.
THE LATEST
Nephron Pharma is rapidly expanding its presence in the area with a $12.5M investment to expand its manufacturing facility and create 125 new jobs.
LifeOmic is planning to build new headquarters at the Indiana University Emerging Technology Center.
Here are five trends job hunters may see in the life sciences next year.
The company has snapped up manufacturing space in North Carolina’s Research Triangle Park to internally produce lentiviral vector for the company’s gene and cell therapies.
Clovis Oncology has solidified its physical footprint in the Bay Area with a 32,000 square foot space it secured for 10 years through property developer TMG Partners.
Gritstone Oncology is hanging a “help wanted” sign as the company looks to staff a new 43,000 square-foot manufacturing facility in Pleasanton, Calif. that will be the center of the company’s immunotherapy manufacturing efforts.
J&J is balking at a plan to build a site in Britain due to concerns over the economy.
Qiagen’s investment will be an expansion of its current operations in that northern England city.
The move is in part related to Brexit, the UK’s exit from the European Union.
Eli Lilly continues to make investments in its diabetes business.